A recent outbreak involving contaminated scopes at Ronald Reagan UCLA Medical Center in Los Angeles left at least two people dead, and officials said scores of other patients potentially were exposed to the dangerous bacteria. At Cedars-Sinai Medical Center, also in Los Angeles, officials this year said four patients had been infected by a superbug after undergoing a duodenoscope procedure. A Connecticut hospital said it had contacted nearly 300 patients who might have been exposed to a dangerous type of drug-resistant E. coli after undergoing duodenoscope procedures.
Such incidents prompted the FDA in February to alert doctors and hospitals that duodenoscopes can be difficult to sanitize between uses and “may facilitate the spread of deadly bacteria.”
Since 2012, other outbreaks have occurred at Advocate Lutheran General Hospital near Chicago, where 44 people were infected, and at the Virginia Mason Medical Center in Seattle, where at least 32 patients became ill and 11 died.
The FDA last week sent warning letters to three major manufacturers of duodenoscopes — Olympus, Pentax and Fujifilm. In particular, regulators cited Pentax and Olympus for failing to inform the FDA that their scopes might have “caused or contributed to a death or serious injury” with 30 days of learning about the incidents. The agency also cited Pentax and Fujifilm for failing to validate their detailed instructions for cleaning the scopes.
The FDA said the companies failed to report problems with the scopes as required by law and in some cases failed to ensure that the devices could be adequately cleaned.
In an e-mail, an Olympus spokesman said the company is “reviewing the FDA’s warning letter so that we can provide the required response in a timely manner.” The company, which is facing lawsuits as a result of the superbug outbreak, issued detailed new cleaning instructions this spring for its devices. The updated instructions include additional cleaning steps and the use of a new “small bristle cleaning brush.”
Pentax said even before last week's warning letter, it had been working closely with the FDA, the Centers for Disease Control and Prevention and healthcare providers to address concerns about the safety of its duodenoscopes. “We take regulatory compliance very seriously and plan to work closely with FDA on the matter. We consider these issues to be of utmost importance. Patient safety is our number one priority,” Mark Koppel, the company's chief medical officer, said in a statement.
Fujifilm said in a statement that it “takes this issue very seriously and is working closely with FDA” to ensure its products meet all regulatory requirements “and pose no risks to the health and safety of the public.”
Duodenoscopes are used in hundreds of thousands of procedures each year in the United States to drain fluids from pancreatic and bile ducts blocked by cancer tumors, gallstones and other conditions. Doctors consider them a key tool in detecting and treating medical problems early and in a minimally invasive way, and regulators and industry officials alike have argued that the benefits of duodenoscopes far outweigh the risks.